Share Price and Basic Stock Data
Last Updated: February 13, 2026, 9:21 pm
| PEG Ratio | 3.09 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Rossari Biotech Ltd operates within the specialty chemicals sector, focusing on manufacturing products for various industries including textiles, personal care, and home care. The company’s revenue has shown a consistent upward trend, with sales reported at ₹1,656 Cr for FY 2023, up from ₹1,483 Cr in FY 2022. The company’s sales are projected to reach ₹2,080 Cr in FY 2025, reflecting a robust growth trajectory. Quarterly sales figures illustrate this growth, with ₹483 Cr in Q2 FY 2024 and ₹464 Cr in Q3 FY 2024, indicating a seasonal fluctuation that is common in the chemicals industry. The trailing twelve months (TTM) revenue stood at ₹2,222 Cr, showcasing the company’s ability to maintain strong sales momentum. This growth is supported by increasing demand in multiple sectors, leveraging Rossari’s diverse product portfolio to capture market share effectively.
Profitability and Efficiency Metrics
Rossari Biotech’s profitability metrics reveal a stable operational performance. The operating profit margin (OPM) for FY 2023 was reported at 13%, with a slight decline to 12% anticipated in FY 2025. The company recorded a net profit of ₹137 Cr for TTM, reflecting a net profit margin of approximately 6.50% for FY 2025. This margin is slightly below typical sector averages, which generally range higher, indicating potential areas for improvement. The interest coverage ratio (ICR) stood at a robust 15.11x, underscoring the company’s strong ability to meet interest obligations. However, the cash conversion cycle (CCC) increased to 101 days in FY 2025, highlighting a potential inefficiency in working capital management. This aspect, combined with a return on equity (ROE) of 12.2%, suggests that while profitability remains stable, there are opportunities to enhance operational efficiency.
Balance Sheet Strength and Financial Ratios
The balance sheet of Rossari Biotech demonstrates a solid financial foundation with total assets reported at ₹2,088 Cr as of September 2025. The company’s reserves have risen to ₹1,240 Cr, reflecting strong retained earnings and financial health. Borrowings stood at ₹353 Cr, indicating a low leverage level with a total debt to equity ratio of 0.15, well within acceptable limits. The price-to-book value (P/BV) ratio is at 2.82x, suggesting the stock is valued at a reasonable premium compared to its book value. Additionally, the company’s current ratio of 1.94x indicates good short-term liquidity, although the quick ratio of 1.28x suggests reliance on inventory for liquidity, which could pose risks in a downturn. Overall, these figures point to a well-managed balance sheet with adequate liquidity and capital structure.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Rossari Biotech reflects a stable investor base, with promoters holding 68.18% of the equity as of March 2025. This substantial promoter holding indicates strong management commitment and alignment with shareholder interests. Foreign Institutional Investors (FIIs) have seen a notable decline in their stake from 8.63% in December 2022 to 2.70% by September 2025, raising concerns about foreign investor confidence. Conversely, Domestic Institutional Investors (DIIs) increased their holdings to 18.18%, indicating a positive outlook from domestic investors. The total number of shareholders stood at 91,387, demonstrating a broad base of retail participation. This mix of ownership suggests a balance between institutional confidence and retail interest, which is crucial for maintaining stock stability and liquidity in the market.
Outlook, Risks, and Final Insight
Looking ahead, Rossari Biotech is poised for growth, driven by its expanding product portfolio and increasing market demand. However, the company faces certain risks, including rising raw material costs which could compress margins and the potential volatility in demand from end-user industries. The increase in the cash conversion cycle indicates a need for improved working capital management to enhance liquidity. On the positive side, the company’s low debt levels provide a buffer against economic fluctuations, while its strong interest coverage ratio suggests financial resilience. If Rossari can successfully navigate these challenges while capitalizing on growth opportunities, it may continue to deliver value to shareholders. The focus on operational efficiency and strategic investments will be critical in sustaining its growth trajectory and enhancing profitability in a competitive landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| HP Adhesives Ltd | 350 Cr. | 38.4 | 62.5/35.0 | 25.2 | 20.5 | 1.04 % | 13.6 % | 9.82 % | 2.00 |
| Haryana Leather Chemicals Ltd | 29.3 Cr. | 59.6 | 88.8/52.0 | 14.3 | 89.6 | 1.68 % | 8.02 % | 5.45 % | 10.0 |
| Hardcastle & Waud Mfg Co Ltd | 49.6 Cr. | 729 | 899/600 | 16.7 | 697 | 0.00 % | 6.31 % | 2.91 % | 10.0 |
| Grauer & Weil (India) Ltd | 3,286 Cr. | 72.5 | 111/68.2 | 21.8 | 22.0 | 0.69 % | 23.3 % | 17.6 % | 1.00 |
| DMCC Speciality Chemicals Ltd | 614 Cr. | 247 | 350/208 | 23.5 | 93.8 | 1.01 % | 14.1 % | 9.97 % | 10.0 |
| Industry Average | 12,979.44 Cr | 740.66 | 101.71 | 182.94 | 0.46% | 12.99% | 25.41% | 6.41 |
Quarterly Result
| Metric | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 389 | 406 | 411 | 483 | 464 | 473 | 490 | 498 | 513 | 580 | 544 | 586 | 582 |
| Expenses | 335 | 352 | 353 | 420 | 400 | 409 | 425 | 432 | 448 | 510 | 476 | 514 | 513 |
| Operating Profit | 54 | 55 | 58 | 64 | 64 | 64 | 65 | 66 | 65 | 69 | 68 | 72 | 69 |
| OPM % | 14% | 13% | 14% | 13% | 14% | 13% | 13% | 13% | 13% | 12% | 12% | 12% | 12% |
| Other Income | 1 | 3 | 2 | 1 | 4 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 1 |
| Interest | 5 | 4 | 6 | 5 | 4 | 3 | 4 | 4 | 5 | 6 | 6 | 6 | 8 |
| Depreciation | 16 | 16 | 14 | 15 | 15 | 16 | 15 | 15 | 18 | 18 | 18 | 18 | 20 |
| Profit before tax | 35 | 37 | 39 | 45 | 48 | 46 | 47 | 48 | 42 | 48 | 46 | 50 | 43 |
| Tax % | 26% | 22% | 26% | 26% | 28% | 25% | 26% | 27% | 25% | 28% | 27% | 26% | 23% |
| Net Profit | 26 | 29 | 29 | 33 | 34 | 34 | 35 | 35 | 32 | 34 | 34 | 37 | 33 |
| EPS in Rs | 4.66 | 5.25 | 5.30 | 5.97 | 6.23 | 6.18 | 6.32 | 6.39 | 5.73 | 6.22 | 6.07 | 6.66 | 5.92 |
Last Updated: February 4, 2026, 9:46 am
Below is a detailed analysis of the quarterly data for Rossari Biotech Ltd based on the most recent figures (Dec 2025) and their trends compared to the previous period:
- For Sales, as of Dec 2025, the value is 582.00 Cr.. The value appears to be declining and may need further review. It has decreased from 586.00 Cr. (Sep 2025) to 582.00 Cr., marking a decrease of 4.00 Cr..
- For Expenses, as of Dec 2025, the value is 513.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 514.00 Cr. (Sep 2025) to 513.00 Cr., marking a decrease of 1.00 Cr..
- For Operating Profit, as of Dec 2025, the value is 69.00 Cr.. The value appears to be declining and may need further review. It has decreased from 72.00 Cr. (Sep 2025) to 69.00 Cr., marking a decrease of 3.00 Cr..
- For OPM %, as of Dec 2025, the value is 12.00%. The value remains steady. There is no change compared to the previous period (Sep 2025) which recorded 12.00%.
- For Other Income, as of Dec 2025, the value is 1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2.00 Cr. (Sep 2025) to 1.00 Cr., marking a decrease of 1.00 Cr..
- For Interest, as of Dec 2025, the value is 8.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6.00 Cr. (Sep 2025) to 8.00 Cr., marking an increase of 2.00 Cr..
- For Depreciation, as of Dec 2025, the value is 20.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 18.00 Cr. (Sep 2025) to 20.00 Cr., marking an increase of 2.00 Cr..
- For Profit before tax, as of Dec 2025, the value is 43.00 Cr.. The value appears to be declining and may need further review. It has decreased from 50.00 Cr. (Sep 2025) to 43.00 Cr., marking a decrease of 7.00 Cr..
- For Tax %, as of Dec 2025, the value is 23.00%. The value appears to be improving (decreasing) as expected. It has decreased from 26.00% (Sep 2025) to 23.00%, marking a decrease of 3.00%.
- For Net Profit, as of Dec 2025, the value is 33.00 Cr.. The value appears to be declining and may need further review. It has decreased from 37.00 Cr. (Sep 2025) to 33.00 Cr., marking a decrease of 4.00 Cr..
- For EPS in Rs, as of Dec 2025, the value is 5.92. The value appears to be declining and may need further review. It has decreased from 6.66 (Sep 2025) to 5.92, marking a decrease of 0.74.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:43 am
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 516 | 600 | 709 | 1,483 | 1,656 | 1,831 | 2,080 | 2,222 |
| Expenses | 438 | 495 | 586 | 1,299 | 1,433 | 1,581 | 1,815 | 1,948 |
| Operating Profit | 78 | 105 | 124 | 184 | 223 | 250 | 265 | 274 |
| OPM % | 15% | 17% | 17% | 12% | 13% | 14% | 13% | 12% |
| Other Income | 1 | 4 | 9 | 13 | 6 | 8 | 5 | 7 |
| Interest | 3 | 4 | 3 | 13 | 22 | 19 | 18 | 22 |
| Depreciation | 12 | 17 | 23 | 48 | 63 | 60 | 67 | 73 |
| Profit before tax | 63 | 88 | 107 | 136 | 144 | 178 | 185 | 186 |
| Tax % | 28% | 26% | 25% | 28% | 26% | 26% | 26% | |
| Net Profit | 46 | 65 | 80 | 98 | 107 | 131 | 136 | 137 |
| EPS in Rs | 103.82 | 12.86 | 15.45 | 17.74 | 19.45 | 23.66 | 24.63 | 24.68 |
| Dividend Payout % | 0% | 4% | 3% | 3% | 3% | 2% | 2% |
YoY Net Profit Growth
| Year | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 41.30% | 23.08% | 22.50% | 9.18% | 22.43% | 3.82% |
| Change in YoY Net Profit Growth (%) | 0.00% | -18.23% | -0.58% | -13.32% | 13.25% | -18.61% |
Rossari Biotech Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 6 years from 2019-2020 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 28% |
| 3 Years: | 12% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 16% |
| 3 Years: | 12% |
| TTM: | -1% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -5% |
| 3 Years: | -14% |
| 1 Year: | -29% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 14% |
| 3 Years: | 13% |
| Last Year: | 12% |
Last Updated: September 5, 2025, 1:10 pm
Balance Sheet
Last Updated: December 4, 2025, 1:53 am
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 10 | 10 | 11 | 11 | 11 | 11 | 11 |
| Reserves | 119 | 277 | 398 | 794 | 904 | 1,037 | 1,174 | 1,240 |
| Borrowings | 8 | 67 | 0 | 8 | 74 | 119 | 218 | 353 |
| Other Liabilities | 118 | 118 | 152 | 442 | 375 | 401 | 482 | 484 |
| Total Liabilities | 250 | 471 | 561 | 1,255 | 1,364 | 1,567 | 1,886 | 2,088 |
| Fixed Assets | 74 | 94 | 181 | 607 | 585 | 578 | 598 | 630 |
| CWIP | 3 | 22 | 0 | 1 | 16 | 47 | 140 | 247 |
| Investments | 0 | 18 | 0 | 36 | 51 | 63 | 84 | 20 |
| Other Assets | 173 | 338 | 379 | 611 | 712 | 880 | 1,063 | 1,190 |
| Total Assets | 250 | 471 | 561 | 1,255 | 1,364 | 1,567 | 1,886 | 2,088 |
Below is a detailed analysis of the balance sheet data for Rossari Biotech Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 11.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 11.00 Cr..
- For Reserves, as of Sep 2025, the value is 1,240.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,174.00 Cr. (Mar 2025) to 1,240.00 Cr., marking an increase of 66.00 Cr..
- For Borrowings, as of Sep 2025, the value is 353.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 218.00 Cr. (Mar 2025) to 353.00 Cr., marking an increase of 135.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 484.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 482.00 Cr. (Mar 2025) to 484.00 Cr., marking an increase of 2.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 2,088.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,886.00 Cr. (Mar 2025) to 2,088.00 Cr., marking an increase of 202.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 630.00 Cr.. The value appears strong and on an upward trend. It has increased from 598.00 Cr. (Mar 2025) to 630.00 Cr., marking an increase of 32.00 Cr..
- For CWIP, as of Sep 2025, the value is 247.00 Cr.. The value appears strong and on an upward trend. It has increased from 140.00 Cr. (Mar 2025) to 247.00 Cr., marking an increase of 107.00 Cr..
- For Investments, as of Sep 2025, the value is 20.00 Cr.. The value appears to be declining and may need further review. It has decreased from 84.00 Cr. (Mar 2025) to 20.00 Cr., marking a decrease of 64.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,190.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,063.00 Cr. (Mar 2025) to 1,190.00 Cr., marking an increase of 127.00 Cr..
- For Total Assets, as of Sep 2025, the value is 2,088.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,886.00 Cr. (Mar 2025) to 2,088.00 Cr., marking an increase of 202.00 Cr..
Notably, the Reserves (1,240.00 Cr.) exceed the Borrowings (353.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Free Cash Flow | 70.00 | 38.00 | 124.00 | 176.00 | 149.00 | 131.00 | 47.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 61 | 57 | 74 | 75 | 78 | 85 | 83 |
| Inventory Days | 59 | 57 | 75 | 63 | 59 | 80 | 90 |
| Days Payable | 114 | 95 | 104 | 61 | 56 | 62 | 73 |
| Cash Conversion Cycle | 6 | 19 | 46 | 76 | 80 | 103 | 101 |
| Working Capital Days | 23 | 22 | 60 | 62 | 49 | 70 | 69 |
| ROCE % | 38% | 29% | 24% | 18% | 18% | 16% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| SBI Small Cap Fund | 2,016,342 | 0.32 | 117.38 | 2,016,798 | 2025-12-08 04:48:22 | -0.02% |
| UTI Flexi Cap Fund | 1,700,000 | 0.4 | 98.97 | 1,747,000 | 2025-12-15 01:39:12 | -2.69% |
| Canara Robeco Small Cap Fund | 1,067,293 | 0.47 | 62.13 | 1,067,293 | 2025-04-22 15:56:53 | 0% |
| Motilal Oswal Small Cap Fund | 855,648 | 0.85 | 49.81 | N/A | N/A | N/A |
| UTI Small Cap Fund | 597,345 | 0.73 | 34.77 | 407,215 | 2025-12-08 01:35:25 | 46.69% |
| UTI Large & Mid Cap Fund | 384,468 | 0.4 | 22.38 | N/A | N/A | N/A |
| UTI Aggressive Hybrid Fund | 361,969 | 0.31 | 21.07 | N/A | N/A | N/A |
| UTI Retirement Fund | 142,863 | 0.17 | 8.32 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 24.66 | 23.67 | 19.46 | 17.81 | 15.56 |
| Diluted EPS (Rs.) | 24.63 | 23.62 | 19.38 | 17.70 | 15.47 |
| Cash EPS (Rs.) | 36.57 | 34.56 | 30.68 | 26.19 | 19.73 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 214.12 | 189.65 | 165.93 | 146.25 | 78.72 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 214.12 | 189.65 | 165.93 | 146.25 | 78.72 |
| Revenue From Operations / Share (Rs.) | 375.74 | 331.35 | 300.22 | 269.36 | 136.60 |
| PBDIT / Share (Rs.) | 48.60 | 46.56 | 41.43 | 35.50 | 25.47 |
| PBIT / Share (Rs.) | 36.49 | 35.63 | 30.02 | 26.77 | 21.07 |
| PBT / Share (Rs.) | 33.27 | 32.12 | 25.97 | 24.47 | 20.49 |
| Net Profit / Share (Rs.) | 24.46 | 23.62 | 19.27 | 17.46 | 15.34 |
| NP After MI And SOA / Share (Rs.) | 24.63 | 23.66 | 19.45 | 17.74 | 15.45 |
| PBDIT Margin (%) | 12.93 | 14.05 | 13.79 | 13.17 | 18.64 |
| PBIT Margin (%) | 9.71 | 10.75 | 9.99 | 9.93 | 15.42 |
| PBT Margin (%) | 8.85 | 9.69 | 8.65 | 9.08 | 15.00 |
| Net Profit Margin (%) | 6.50 | 7.12 | 6.41 | 6.48 | 11.22 |
| NP After MI And SOA Margin (%) | 6.55 | 7.13 | 6.47 | 6.58 | 11.30 |
| Return on Networth / Equity (%) | 11.50 | 12.47 | 11.71 | 12.13 | 19.62 |
| Return on Capital Employeed (%) | 14.85 | 17.15 | 16.22 | 15.31 | 26.61 |
| Return On Assets (%) | 7.19 | 8.31 | 7.84 | 7.77 | 14.29 |
| Long Term Debt / Equity (X) | 0.08 | 0.03 | 0.03 | 0.00 | 0.00 |
| Total Debt / Equity (X) | 0.15 | 0.10 | 0.08 | 0.01 | 0.00 |
| Asset Turnover Ratio (%) | 1.20 | 1.25 | 1.26 | 1.63 | 1.37 |
| Current Ratio (X) | 1.94 | 1.99 | 2.08 | 2.07 | 2.36 |
| Quick Ratio (X) | 1.28 | 1.32 | 1.54 | 1.42 | 1.73 |
| Inventory Turnover Ratio (X) | 6.53 | 5.22 | 5.70 | 6.80 | 5.66 |
| Dividend Payout Ratio (NP) (%) | 2.02 | 2.11 | 2.56 | 2.81 | 3.16 |
| Dividend Payout Ratio (CP) (%) | 1.35 | 1.44 | 1.61 | 1.88 | 2.46 |
| Earning Retention Ratio (%) | 97.98 | 97.89 | 97.44 | 97.19 | 96.84 |
| Cash Earning Retention Ratio (%) | 98.65 | 98.56 | 98.39 | 98.12 | 97.54 |
| Interest Coverage Ratio (X) | 15.11 | 13.28 | 10.24 | 15.44 | 44.20 |
| Interest Coverage Ratio (Post Tax) (X) | 8.60 | 7.74 | 5.76 | 8.60 | 27.62 |
| Enterprise Value (Cr.) | 3475.13 | 3801.34 | 3233.01 | 4985.62 | 5300.00 |
| EV / Net Operating Revenue (X) | 1.67 | 2.08 | 1.95 | 3.36 | 7.47 |
| EV / EBITDA (X) | 12.91 | 14.78 | 14.15 | 25.51 | 40.08 |
| MarketCap / Net Operating Revenue (X) | 1.61 | 2.04 | 1.98 | 3.39 | 7.60 |
| Retention Ratios (%) | 97.97 | 97.88 | 97.43 | 97.18 | 96.83 |
| Price / BV (X) | 2.82 | 3.56 | 3.59 | 6.25 | 13.18 |
| Price / Net Operating Revenue (X) | 1.61 | 2.04 | 1.98 | 3.39 | 7.60 |
| EarningsYield | 0.04 | 0.03 | 0.03 | 0.01 | 0.01 |
After reviewing the key financial ratios for Rossari Biotech Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 24.66. This value is within the healthy range. It has increased from 23.67 (Mar 24) to 24.66, marking an increase of 0.99.
- For Diluted EPS (Rs.), as of Mar 25, the value is 24.63. This value is within the healthy range. It has increased from 23.62 (Mar 24) to 24.63, marking an increase of 1.01.
- For Cash EPS (Rs.), as of Mar 25, the value is 36.57. This value is within the healthy range. It has increased from 34.56 (Mar 24) to 36.57, marking an increase of 2.01.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 214.12. It has increased from 189.65 (Mar 24) to 214.12, marking an increase of 24.47.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 214.12. It has increased from 189.65 (Mar 24) to 214.12, marking an increase of 24.47.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 375.74. It has increased from 331.35 (Mar 24) to 375.74, marking an increase of 44.39.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 48.60. This value is within the healthy range. It has increased from 46.56 (Mar 24) to 48.60, marking an increase of 2.04.
- For PBIT / Share (Rs.), as of Mar 25, the value is 36.49. This value is within the healthy range. It has increased from 35.63 (Mar 24) to 36.49, marking an increase of 0.86.
- For PBT / Share (Rs.), as of Mar 25, the value is 33.27. This value is within the healthy range. It has increased from 32.12 (Mar 24) to 33.27, marking an increase of 1.15.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 24.46. This value is within the healthy range. It has increased from 23.62 (Mar 24) to 24.46, marking an increase of 0.84.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 24.63. This value is within the healthy range. It has increased from 23.66 (Mar 24) to 24.63, marking an increase of 0.97.
- For PBDIT Margin (%), as of Mar 25, the value is 12.93. This value is within the healthy range. It has decreased from 14.05 (Mar 24) to 12.93, marking a decrease of 1.12.
- For PBIT Margin (%), as of Mar 25, the value is 9.71. This value is below the healthy minimum of 10. It has decreased from 10.75 (Mar 24) to 9.71, marking a decrease of 1.04.
- For PBT Margin (%), as of Mar 25, the value is 8.85. This value is below the healthy minimum of 10. It has decreased from 9.69 (Mar 24) to 8.85, marking a decrease of 0.84.
- For Net Profit Margin (%), as of Mar 25, the value is 6.50. This value is within the healthy range. It has decreased from 7.12 (Mar 24) to 6.50, marking a decrease of 0.62.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 6.55. This value is below the healthy minimum of 8. It has decreased from 7.13 (Mar 24) to 6.55, marking a decrease of 0.58.
- For Return on Networth / Equity (%), as of Mar 25, the value is 11.50. This value is below the healthy minimum of 15. It has decreased from 12.47 (Mar 24) to 11.50, marking a decrease of 0.97.
- For Return on Capital Employeed (%), as of Mar 25, the value is 14.85. This value is within the healthy range. It has decreased from 17.15 (Mar 24) to 14.85, marking a decrease of 2.30.
- For Return On Assets (%), as of Mar 25, the value is 7.19. This value is within the healthy range. It has decreased from 8.31 (Mar 24) to 7.19, marking a decrease of 1.12.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.08. This value is below the healthy minimum of 0.2. It has increased from 0.03 (Mar 24) to 0.08, marking an increase of 0.05.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.15. This value is within the healthy range. It has increased from 0.10 (Mar 24) to 0.15, marking an increase of 0.05.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.20. It has decreased from 1.25 (Mar 24) to 1.20, marking a decrease of 0.05.
- For Current Ratio (X), as of Mar 25, the value is 1.94. This value is within the healthy range. It has decreased from 1.99 (Mar 24) to 1.94, marking a decrease of 0.05.
- For Quick Ratio (X), as of Mar 25, the value is 1.28. This value is within the healthy range. It has decreased from 1.32 (Mar 24) to 1.28, marking a decrease of 0.04.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 6.53. This value is within the healthy range. It has increased from 5.22 (Mar 24) to 6.53, marking an increase of 1.31.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 2.02. This value is below the healthy minimum of 20. It has decreased from 2.11 (Mar 24) to 2.02, marking a decrease of 0.09.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 1.35. This value is below the healthy minimum of 20. It has decreased from 1.44 (Mar 24) to 1.35, marking a decrease of 0.09.
- For Earning Retention Ratio (%), as of Mar 25, the value is 97.98. This value exceeds the healthy maximum of 70. It has increased from 97.89 (Mar 24) to 97.98, marking an increase of 0.09.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 98.65. This value exceeds the healthy maximum of 70. It has increased from 98.56 (Mar 24) to 98.65, marking an increase of 0.09.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 15.11. This value is within the healthy range. It has increased from 13.28 (Mar 24) to 15.11, marking an increase of 1.83.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 8.60. This value is within the healthy range. It has increased from 7.74 (Mar 24) to 8.60, marking an increase of 0.86.
- For Enterprise Value (Cr.), as of Mar 25, the value is 3,475.13. It has decreased from 3,801.34 (Mar 24) to 3,475.13, marking a decrease of 326.21.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.67. This value is within the healthy range. It has decreased from 2.08 (Mar 24) to 1.67, marking a decrease of 0.41.
- For EV / EBITDA (X), as of Mar 25, the value is 12.91. This value is within the healthy range. It has decreased from 14.78 (Mar 24) to 12.91, marking a decrease of 1.87.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.61. This value is within the healthy range. It has decreased from 2.04 (Mar 24) to 1.61, marking a decrease of 0.43.
- For Retention Ratios (%), as of Mar 25, the value is 97.97. This value exceeds the healthy maximum of 70. It has increased from 97.88 (Mar 24) to 97.97, marking an increase of 0.09.
- For Price / BV (X), as of Mar 25, the value is 2.82. This value is within the healthy range. It has decreased from 3.56 (Mar 24) to 2.82, marking a decrease of 0.74.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.61. This value is within the healthy range. It has decreased from 2.04 (Mar 24) to 1.61, marking a decrease of 0.43.
- For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.04, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Rossari Biotech Ltd:
- Net Profit Margin: 6.5%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 14.85% (Industry Average ROCE: 12.99%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 11.5% (Industry Average ROE: 25.41%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 8.6
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.28
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 21.1 (Industry average Stock P/E: 101.71)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.15
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 6.5%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Speciality - Others | Rossari House, Golden Oak, LBS Marg, Surya Nagar, Mumbai Maharashtra 400079 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Edward Menezes | Executive Chairman |
| Mr. Sunil Chari | Managing Director |
| Mr. Aseem Dhru | Independent Director |
| Ms. Aparna Sharma | Independent Director |
| Ms. Esha Achan | Independent Director |
| Mr. Gurudas Aras | Independent Director |
FAQ
What is the intrinsic value of Rossari Biotech Ltd?
Rossari Biotech Ltd's intrinsic value (as of 13 February 2026) is ₹497.68 which is 5.02% lower the current market price of ₹524.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹2,908 Cr. market cap, FY2025-2026 high/low of ₹768/502, reserves of ₹1,240 Cr, and liabilities of ₹2,088 Cr.
What is the Market Cap of Rossari Biotech Ltd?
The Market Cap of Rossari Biotech Ltd is 2,908 Cr..
What is the current Stock Price of Rossari Biotech Ltd as on 13 February 2026?
The current stock price of Rossari Biotech Ltd as on 13 February 2026 is ₹524.
What is the High / Low of Rossari Biotech Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Rossari Biotech Ltd stocks is ₹768/502.
What is the Stock P/E of Rossari Biotech Ltd?
The Stock P/E of Rossari Biotech Ltd is 21.1.
What is the Book Value of Rossari Biotech Ltd?
The Book Value of Rossari Biotech Ltd is 226.
What is the Dividend Yield of Rossari Biotech Ltd?
The Dividend Yield of Rossari Biotech Ltd is 0.10 %.
What is the ROCE of Rossari Biotech Ltd?
The ROCE of Rossari Biotech Ltd is 15.8 %.
What is the ROE of Rossari Biotech Ltd?
The ROE of Rossari Biotech Ltd is 12.2 %.
What is the Face Value of Rossari Biotech Ltd?
The Face Value of Rossari Biotech Ltd is 2.00.